Drug-resistant TB drug Dovprela applies for reimbursement

By Eo, Yun-Ho | translator Alice Kang

22.03.15 16:44:51

가나다라 0

Treatment for Drug-resistant TB Companies rarely developed due to lack of profit…first treatment to be introduced in 50 years

Demonstrated efficacy through Phase III trial…reduced treatment period with better efficacy

‘Dovprela,’ the first new drug introduced in the field of tuberculosis in 50 years, is attempting reimbursement listing in Korea.

According to industry sources, Viatris Korea has submitted an application for the reimbursement listing of its multi-drug resistant tuberculosis treatment, Dovprela (pretomanid).

Dovprela, which was first approved in September in the US and in October in Korea, is indicated in combination with bedaquiline and linezolid to treat adult patients with extensively drug-resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) pulmonary tuberculosis (TB).

Pretomanid is the first new drug introduced in the field in 50 year

Eo, Yun-Ho(unkindfish@dailypharm.com)

If you want to see the full article, please JOIN US (click)